Patents Represented by Attorney Scott A. Chapple
  • Patent number: 8323630
    Abstract: The present invention is directed to the provision of multi-dose, self-preserved ophthalmic compositions. The compositions possess sufficient antimicrobial activity to satisfy USP preservative efficacy requirements, as well as similar preservative standards (e.g., EP and JP), without requiring the presence of conventional anti-microbial preservative agents, such as benzalkonium chloride. The compositions are effectively preserved by a balanced ionic buffer system containing zinc ions at a concentration of 0.04 to 0.9 mM, preferably 0.04 to 0.4 mM. One aspect of the balanced buffer system is limitation of the amount of buffering anions present to a concentration of 15 mM or less, preferably 5 mM or less. In a preferred embodiment, the compositions also contain borate or, most preferably, one or more borate/polyol complexes. The use of propylene glycol as the polyol in such complexes is strongly preferred.
    Type: Grant
    Filed: April 14, 2011
    Date of Patent: December 4, 2012
    Assignee: Alcon Research, Ltd.
    Inventors: Bhagwati P. Kabra, Masood A. Chowhan, L. Wayne Schneider, Wesley Wehsin Han
  • Patent number: 8313754
    Abstract: Ophthalmic compositions suitable for use as artificial tears or as vehicles for ophthalmic drugs are disclosed. The compositions contain a combination of two polymers that have a synergistic effect on viscosity.
    Type: Grant
    Filed: April 11, 2011
    Date of Patent: November 20, 2012
    Assignee: Novartis AG
    Inventors: Masood A. Chowhan, Huagang Chen
  • Patent number: 8268299
    Abstract: The present invention is directed to the provision of multi-dose, self-preserved ophthalmic compositions. The compositions possess sufficient antimicrobial activity to satisfy USP preservative efficacy requirements, as well as similar preservative standards (e.g., EP and JP), without requiring the presence of conventional anti-microbial preservative agents, such as benzalkonium chloride. The compositions are effectively preserved by a balanced ionic buffer system containing zinc ions at a concentration of 0.04 to 0.9 mM, preferably 0.04 to 0.4 mM. One aspect of the balanced buffer system is limitation of the amount of buffering anions present to a concentration of 15 mM or less, preferably 5 mM or less. In a preferred embodiment, the compositions also contain borat or, most preferably, one or more borate/polyol complexes. The use of propylene glycol as the polyol in such complexes is strongly preferred.
    Type: Grant
    Filed: September 20, 2007
    Date of Patent: September 18, 2012
    Assignee: Alcon Research, Ltd.
    Inventors: Bhagwati P. Kabra, Masood A. Chowhan, L. Wayne Schneider, Wesley Wehsin Han
  • Patent number: 8262948
    Abstract: Disclosed are ophthalmic device materials having improved light transmission characteristics. The materials contain a combination of certain UV absorbers and blue-light absorbing chromophores.
    Type: Grant
    Filed: April 27, 2011
    Date of Patent: September 11, 2012
    Assignee: Novartis AG
    Inventors: Walter R. Laredo, Ali E. Akinay
  • Patent number: 8263721
    Abstract: Disclosed are soft, high refractive index device materials having improved strength. The materials contain a polystyrene macromer.
    Type: Grant
    Filed: April 2, 2009
    Date of Patent: September 11, 2012
    Assignee: Novartis AG
    Inventor: Douglas C. Schlueter
  • Patent number: 8178582
    Abstract: The present invention is directed to the provision of pharmaceutical compositions. The compositions include a therapeutic agent and a relatively low amount of surfactant for providing higher bioavailability of the therapeutic agent. The compositions are particularly desirable as ophthalmic compositions in which the therapeutic agent is a prostaglandin such as travoprost and the surfactant is a vegetable oil such as castor oil.
    Type: Grant
    Filed: March 13, 2009
    Date of Patent: May 15, 2012
    Assignee: Alcon Research, Ltd.
    Inventor: Bhagwati P. Kabra
  • Patent number: 8101582
    Abstract: Ophthalmic pharmaceutical compositions containing tobramycin, dexamethasone and deacetylated xanthan gum are described. The compositions provide longer ocular retention for enhanced ocular bioavailability of tobramycin and dexamethasone. In a preferred embodiment, the compositions also provide for improved suspension of dexamethasone. The concentration of ionizable species in the compositions is controlled so as to prevent precipitation of the xanthan gum as a result of ionic interactions between tobramycin and xanthan gum, while allowing for a restoration of viscosity upon topical application of the compositions to the eye. The use of deacetylated xanthan gum is disclosed, so as to avoid formulation instability caused by pH drift during storage.
    Type: Grant
    Filed: July 22, 2010
    Date of Patent: January 24, 2012
    Assignee: Alcon Research, Ltd.
    Inventor: Bhagwati P. Kabra
  • Patent number: 8084054
    Abstract: Drug delivery film compositions containing a combination of a water-soluble, film-forming polymers and a fatty acid glyceride or ester are suitable for delivering ophthalmic drugs.
    Type: Grant
    Filed: June 30, 2003
    Date of Patent: December 27, 2011
    Assignee: Novartis AG
    Inventors: Bhagwati P. Kabra, Janet D. Howie, Youqin Tian, David Allen Marsh, Gustav Graff
  • Patent number: 7998197
    Abstract: Exemplary embodiments provide a coated intraocular lens that has a lens body with a first refractive index and an anti-reflective coating. The coating covers at least a portion of the lens body and has a second index of refraction that is less than the first index of refraction of the lens body. The anti-reflective coating reduces the intensity of reflections produced from off axis light incident on the lens body by at least a factor of 2.5 times and enhancing light transmission.
    Type: Grant
    Filed: July 11, 2008
    Date of Patent: August 16, 2011
    Assignee: Novartis AG
    Inventors: Xiaoxiao Zhang, Kamal K. Das
  • Patent number: 7988729
    Abstract: An exemplary embodiment provides a biocompatible polymer composition suitable for making intraocular lenses, especially posterior chamber phakic lenses, that includes a hydrogel having an equilibrium water content of less than about 55 wt. %. The hydrogel has a refractive index greater than about 1.41 and a sodium ion flux between about 16 to about 20 ?eq-mm/hr/cm2.
    Type: Grant
    Filed: July 16, 2008
    Date of Patent: August 2, 2011
    Assignee: Novartis AG
    Inventor: Charles Freeman
  • Patent number: 7947295
    Abstract: Ophthalmic compositions suitable for use as artificial tears or as vehicles for ophthalmic drugs are disclosed. The compositions contain a combination of two polymers that have a synergistic effect on viscosity.
    Type: Grant
    Filed: February 9, 2007
    Date of Patent: May 24, 2011
    Assignee: Alcon, Inc.
    Inventors: Masood A. Chowhan, Huagang Chen
  • Patent number: 7914803
    Abstract: Ophthalmic compositions suitable for use as artificial tears or as vehicles for ophthalmic drugs are disclosed. The compositions contain a combination of three polymers that have a synergistic effect on viscosity.
    Type: Grant
    Filed: February 9, 2007
    Date of Patent: March 29, 2011
    Assignee: Alcon, Inc.
    Inventors: Masood A. Chowhan, Huagang Chen
  • Patent number: 7795316
    Abstract: Ophthalmic pharmaceutical compositions containing tobramycin, dexamethasone and deacetylated xanthan gum are described. The compositions provide longer ocular retention for enhanced ocular bioavailability of tobramycin and dexamethasone. In a preferred embodiment, the compositions also provide for improved suspension of dexamethasone. The concentration of ionizable species in the compositions is controlled so as to prevent precipitation of the xanthan gum as a result of ionic interactions between tobramycin and xanthan gum, while allowing for a restoration of viscosity upon topical application of the compositions to the eye. The use of deacetylated xanthan gum is disclosed, so as to avoid formulation instability caused by pH drift during storage.
    Type: Grant
    Filed: December 19, 2007
    Date of Patent: September 14, 2010
    Assignee: Alcon Research, Ltd.
    Inventor: Bhagwati P. Kabra
  • Patent number: 7727549
    Abstract: Otic compositions are disclosed. The compositions contain an otic drug and a carrier comprising a low molecular weight compound. The compositions do not drain out of the ear after administration.
    Type: Grant
    Filed: June 30, 2003
    Date of Patent: June 1, 2010
    Assignee: Alcon, Inc.
    Inventor: Bhagwati P. Kabra
  • Patent number: 7709012
    Abstract: Ophthalmic compositions suitable for use as artificial tears or as vehicles for ophthalmic drugs are disclosed. The compositions contain a combination of two polymers that have a synergistic effect on viscosity.
    Type: Grant
    Filed: June 8, 2004
    Date of Patent: May 4, 2010
    Assignee: Alcon, Inc.
    Inventors: Masood A. Chowhan, Huagang Chen
  • Patent number: 7691918
    Abstract: Disclosed are ophthalmic device materials having improved light transmission characteristics. The materials contain a combination of certain UV absorbers and blue-light absorbing chromophores.
    Type: Grant
    Filed: October 12, 2007
    Date of Patent: April 6, 2010
    Assignee: Alcon, Inc.
    Inventors: David L. Jinkerson, Joseph I. Weinschenk, III, Mutlu Karakelle
  • Patent number: 7652076
    Abstract: Disclosed are soft, high refractive index device materials having improved strength. The materials contain a monofunctional or difunctional, acrylate or methacrylate terminated aromatic functional methacrylic or acrylic macromer.
    Type: Grant
    Filed: June 12, 2006
    Date of Patent: January 26, 2010
    Assignee: Alcon, Inc.
    Inventors: Douglas C. Schlueter, Mutlu Karakelle
  • Patent number: 7621907
    Abstract: An implantable medicament delivery device includes a core body which further includes a single basin or multiple smaller basins for containing a drug or a medicament. Each basin is covered by a screen. The implantable drug delivery device is placed within the body of an animal, and the drug is allowed to diffuse through the holes in the screen to provide treatment of a disease or condition.
    Type: Grant
    Filed: March 11, 2003
    Date of Patent: November 24, 2009
    Assignee: Alcon, Inc.
    Inventor: Theron Robert Rodstrom
  • Patent number: 7618620
    Abstract: Ophthalmic compositions suitable for use as artificial tears or as vehicles for ophthalmic drugs are disclosed. The compositions contain a combination of three polymers that have a synergistic effect on viscosity.
    Type: Grant
    Filed: October 18, 2007
    Date of Patent: November 17, 2009
    Assignee: Alcon, Inc.
    Inventors: Masood A. Chowhan, Huagang Chen
  • Patent number: 7485607
    Abstract: The use of NIPAM polymers to prevent or reduce the formation of protein deposits on the surfaces of medical devices is described. The invention is particularly directed to reduction of the adsorption of proteins on surfaces of contact lenses and other medical prosthetics.
    Type: Grant
    Filed: May 27, 2008
    Date of Patent: February 3, 2009
    Assignee: Alcon, Inc.
    Inventor: Howard Allen Ketelson